Article Text

Download PDFPDF
Archimedes: does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
  1. Barbara Schmidt1,
  2. Robin S Roberts1,
  3. Peter Davis2,
  4. Lex W Doyle2,
  5. for the Steering Committee of the Caffeine for Apnea of Prematurity (CAP) trial
  1. 1Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
  2. 2Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia
  1. Correspondence to Barbara Schmidt, Hospital of the University of Pennsylvania, University of Pennsylvania, Ravdin 8, 3400 Spruce Street, Philadelphia, PA 19104, USA; Schmidt{at} or{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We were surprised by some of the comments of Winckworth and Powell1 about the Caffeine for Apnea of Prematurity (CAP) trial.2 The authors concluded that the CAP trial had a ‘large preanalysis dropout rate (up to 15%)’. We correct this serious misunderstanding in table 1 which shows the number of children who had missing data for the outcome of death or disability at 18 months, …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.